TherapeuticsMD Q1 net loss narrows to $636K; license revenue up 26%

TherapeuticsMD, Inc.

2025-Q1 EPS reported -$0.06 revenue$393,000

Net loss from continuing ops $(636)K ($0.06/sh) vs $(809)K ($0.07/sh) in Q1 2024.
License revenue $393K, up 25.8% from $313K, driven by Mayne License sales changes.
Operating expenses $1,264K, down 13.1% from prior year on royalty business efficiencies.
Cash and equivalents $5.7M at March 31, 2025; no debt disclosed.
Company continues evaluating strategic alternatives including M&A or asset sale.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.